Author:
Fritzsche Jeska A.,Klein Amir,Beekman Maarten J.,van Hooft Jeanin E.,Sidhu Mayenaaz,Schoeman Scott,Fockens Paul,Bourke Michael J.,Voermans Rogier P.
Abstract
Abstract
Background
Endoscopic papillectomy (EP) is considered a relatively safe and minimally invasive treatment for papillary adenomas. In the literature a significant risk for local recurrence is described. The aim of this study was to evaluate long-term recurrence rates and time-to-recurrence. Additionally, risk factors for recurrence, malignancy and adverse events were studied.
Methods
This is a retrospective study in consecutive patients with papillary adenomas who underwent EP in two tertiary referral hospitals between 2001 and 2018. Primary outcome was recurrence in patients with at least 1-year endoscopic follow-up. Secondary outcomes were surgery free survival, adverse events, and mortality within 30 days after the index procedure.
Results
A total of 259 patients were found eligible [median age 66 years, 130 male (50.2%)]. Forty-three patients were known with familial adenomatous polyposis (FAP) (16.6%). At least 1-year endoscopic follow-up was available in 154 patients with a total follow-up of 586 person-years and median of 40 months [interquartile range (IQR) 25–75]. Recurrence occurred in 24 cases (15.6%) of which 8 were known with FAP, leading to a recurrence incidence rate of 4.1 per 100 person-years with a median time-to-recurrence of 29 months (IQR 14.75–59.5). Fifty-three patients underwent at least 5-year follow-up, in 6 (11.3%) of them recurrence was encountered after 5 years of which four were known with FAP. No risk factors for recurrence could be identified. Adverse events occurred in 50/259 patients (19.3%). One patient died within 30 days after the procedure. Papillary stenosis occurred in 19/259 (7.3%) of the patients. There were no cases of malignant degeneration during follow-up.
Conclusions
Recurrence after EP occurs in a significant proportion of patients and occurs even 5 years after EP. This emphasizes the need for long-term follow-up. We advise to consider at least 5-year follow-up in case of a sporadic adenoma, unless comorbidity makes follow-up clinically irrelevant.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Rosenberg J, Welch JP, Pyrtek LJ, Walker M, Trowbridge P (1986) Benign villous adenomas of the ampulla of Vater. Cancer 58:1563–1568
2. Spigelman AD, Williams CB, Domizio P, Phillips RKS (1989) Upper gastro intestinal cancer in patients with familial adenomatous polyposis. Lancet 2:783–785
3. Hayes DH, Bolton JS, Willis GW, Bowen JC (1952) Carcinoma of the ampulla of Vater. Am J Surg 83:20–25
4. El Hajj II, Coté GA (2013) Endoscopic diagnosis and management of ampullary lesions. Gastrointest Endosc Clin N Am 23:95–109
5. Seifert E, Schulte F, Stolte M (1992) Adenoma and carcinoma of the duodenum and papilla of Vater: a clinicopathologic study. Am J Gastroenterol 87:37–42
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献